Trial Profile
A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment, defined as HBV-DNA levels greater than 10.000 copies/ml after an ADV or ADV+LAM treatment of greater than 48 weeks.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2013
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms OptiB
- 25 Aug 2011 New trial record